Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
Bio Pharma Dive
NOVEMBER 28, 2023
Tuesday’s deal signals the pharmaceutical giant's confidence in Avidity Biosciences and its so-called antibody oligonucleotide conjugates.
RNA therapy firm Avidity files $400m placement
pharmaphorum
MARCH 3, 2024
Avidity Biosciences files $400m private placement as it prepares for phase 3 trial of lead antibody oligonucleotide conjugate AOC 1001 in rare disease DM1
RNA 
105
105 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Grant supports discovery of RNA-targeting Henipavirus therapeutics
Drug Discovery World
JUNE 7, 2023
Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. PRROTECT is designed to accelerate R&D timelines for neutralising antibodies and create a flexible manufacturing network to deliver such therapeutics in the event of a future pandemic.
RNA 52
52 
Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal
pharmaphorum
MAY 12, 2021
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . The post Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal appeared first on.
RNA 76
76 
Avidity Biosciences files patent for method of delivering oligonucleotide for treating muscular dystrophy
Pharmaceutical Technology
DECEMBER 21, 2023
A patent has been filed for an intravenous administration of an anti-transferrin receptor antibody linked to an oligonucleotide, targeting the degradation of DUX4 mRNA and biomarker RNA in muscle cells. Discover a groundbreaking method for treating Facioscapulohumeral muscular dystrophy (FSHD) and other muscular dystrophies.
RNA 100
100 
Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class
pharmaphorum
MAY 11, 2021
Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. The technology is designed to replace antibodies, which have become standard therapy in many diseases but are complicated and expensive to manufacture.
RNA 98
98 
Lilly’s antibody therapy cuts hospitalisation rates in COVID-19
pharmaphorum
SEPTEMBER 17, 2020
Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease. The double-blind placebo-controlled antibody study involved patients with symptoms outside hospitals, who were treated with four different dose strengths.
Antibody 129
129 
Biologists isolated the coronavirus nucleoprotein in its pure form to improve the accuracy and sensitivity of the antibody tests
Scienmag
FEBRUARY 7, 2022
It folds the RNA of the virus into a compact structure. COVID-19 patients usually develop antibodies (immunity proteins that are specifically […]. The SARS-CoV-2 nucleoprotein is the main protein in viral particles.
Antibody 82
82 
Conversations from ESMO Targeted Anticancer Therapies Congress 2024
Drug Discovery World
MARCH 26, 2024
For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. We were excited to unveil data showing that two distinct chemical series exhibit METTL1 inhibition in vitro at low nanomolar concentrations with minimal interference with other RNA and protein methyltransferases.
RNA 64
64 
Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-0184?
Pharmaceutical Technology
JUNE 6, 2023
The therapeutic candidate consists of messenger RNA (mRNA) encoding for relaxin. It is developed based on messenger RNA expression and N2GL formulation platform. Moderna Overview Moderna is a biotechnology company that focuses on the development of messenger RNA therapeutics and vaccines.
RNA 100
100 
Avidity Biosciences granted FDA Fast Track Designation for Duchenne Muscular Dystrophy treatment
BioPharma Reporter
APRIL 24, 2023
Avidity Biosciences, a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1044.
RNA 59
59 
Positive initial results for srRNA rabies vaccine
Drug Discovery World
FEBRUARY 19, 2024
At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus. Preliminary data show that the surrogate metric of protection (RVNA≥0.5)
Vaccination 52
52 
US FDA grants Fast Track status for Avidity’s AOC 1020 to treat FSHD
Pharmaceutical Technology
JANUARY 19, 2023
It comprises a monoclonal antibody (mAb) attached to the transferrin receptor 1 (TfR1) conjugated with a DUX4 mRNA that targets siRNA. We look forward to working collaboratively with the FDA to bring the first RNA therapy directly targeting DUX4 to patients as quickly as possible.”
Gene Expression 246
246 
Health Canada grants approval for Moderna’s Covid-19 vaccine in children
Pharmaceutical Technology
JULY 15, 2022
Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada.
Vaccination 264
264 
miRecule and Sanofi partner to develop muscular dystrophy therapy
Pharmaceutical Technology
OCTOBER 5, 2022
miRecule and Sanofi have entered a strategic partnership and exclusive licence agreement for the development and commercialisation of an antibody-RNA conjugate (ARC) to treat facioscapulohumeral muscular dystrophy (FSHD). The anti-DUX4 RNA therapy was discovered using the DREAmiR platform of miRecule.
Development 130
130 
Avidity Prepares to Transition into Clinical Company in 2021
BioSpace
JANUARY 20, 2021
California-based Avidity Biosciences has a goal of disrupting the way RNA-based therapies are delivered to patients through its Antibody-Oligonucleotide Conjugates (AOCs) platform.
RNA 81
81 
Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical
Delveinsight
SEPTEMBER 23, 2021
The biotech has evolved a T-cell receptor-like antibody to damage a selected immune checkpoint in oncology. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising.
RNA 61
61 
AI model proactively predicts if a COVID-19 test might be positive or not
Medical Xpress
DECEMBER 13, 2022
Molecular tests measure the presence of viral SARS-CoV-2 RNA while serology tests detect the presence of antibodies triggered by the SARS-CoV-2 virus. Serology (blood) and molecular tests are the two most commonly used methods for rapid COVID-19 testing. Because COVID-19 tests use different mechanisms, they vary significantly.
RNA 75
75 
Sanofi wagers $400m on miRecule muscular dystrophy therapy
pharmaphorum
OCTOBER 5, 2022
Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018.
RNA 105
105 
Biopharma investment drops by nearly 50% in 2022
Drug Discovery World
MAY 22, 2023
Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Pharma is also keen to access next generation RNA platforms, such as self-amplifying RNAs derived from the genomes of positive-strand RNA viruses.
RNA 52
52 
HIV vaccines suffer setbacks but new approaches could turn the tide
Pharmaceutical Technology
FEBRUARY 3, 2023
Now, the HIV research community is setting its sights on vaccines that are in earlier stages of development, based on new approaches like messenger RNA (mRNA) -based vaccines or those using human cytomegalovirus (HCMV) vectors. This response was also seen in the RV 144 trial, she notes.
Vaccination 293
293 
Moderna seeks FDA EUA for Covid-19 booster vaccine
Pharmaceutical Technology
AUGUST 24, 2022
Mode rna has submitted an application to the US Food and Drug Administration (FDA) to obtain emergency use authorization (EUA) for mRNA-1273.222, its BA.4/BA.5 As against a 50µg booster dose of mRNA-1273 in priorly uninfected subjects, mRNA-1273.214 demonstrated superior neutralising antibody response against Omicron BA.1 1 subvariant.
Vaccination 130
130 
DDW top reads in 2023
Drug Discovery World
DECEMBER 21, 2023
Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.
Gene Therapy 59
59 
DDW Cancer Research Summit: Industry experts join the panel
Drug Discovery World
OCTOBER 11, 2023
The main presentations will be followed by a panel discussion on how these new approaches – e.g., engineered proteins, antibodies, micro RNA, nanocarriers, antibody drug conjugates – can help address unmet need in oncology.
Research 52
52 
Leading innovators in flavivirus vaccine components
Pharmaceutical Technology
FEBRUARY 15, 2023
Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Vaccination 130
130 
Leading innovators in mammalian expression vectors for the pharmaceutical industry
Pharmaceutical Technology
FEBRUARY 14, 2023
Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.
In-Vivo 130
130 
DDW announces first summit on advances in cancer research
Drug Discovery World
OCTOBER 5, 2023
The presentations will be followed by a panel discussion addressing new drug discovery and development concepts and tools in cancer research, and how these new approaches – e.g. engineered proteins, antibodies, micro RNA, nanocarriers, antibody drug conjugates – can help address unmet need in oncology.
Research 52
52 
Can The Next Generation Drug Conjugates Revolutionize The Rare Disorder Domain?
Roots Analysis
OCTOBER 13, 2023
As a result, in late nineties, the conjugation of drug with biological entities such as antibodies emerged as a possible solution for targeting earlier undruggable entities. However, it was not until 2000 when the first drug conjugate in the form of antibody drug conjugate (ADC) was approved by the USFDA.
Drugs 40
40 
CureVac Touts Positive Preclinical Data for COVID-19 Vaccine | 2020-10-26
The Pharma Data
OCTOBER 25, 2020
The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice. German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response.
Vaccination 52
52 
This week in drug discovery (9-13 January)
Drug Discovery World
JANUARY 13, 2023
Alliance to develop circular RNA-based therapeutics . Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. . Collaboration to identify up to 10 novel target-antibody pairs .
Drugs 52
52 
Evox Therapeutics acquires exosome AAV technology from Codiak
Drug Discovery World
JUNE 22, 2023
This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies. “We The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).
Gene Therapy 52
52 
UNC team discovers interactions vital for hepatitis A virus replication
Pharmaceutical Technology
JULY 5, 2022
On leaving the liver cells, the virus hijacks bits of cell membrane and conceals itself from antibodies that would have isolated the virus before it travelled far through the bloodstream. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.
Protein 130
130 
LabCorp’s Innovative High-Speed COVID-19 Test Gets Emergency Use Authorization from the FDA
XTalks
OCTOBER 7, 2020
While the new test is based on RT-PCR molecular detection, it utilizes a high-throughput technique involving a new heat-based extraction method and enhanced technology to extract RNA from samples for COVID-19 testing. LabCorp was given the green light for the test by the FDA last week, which is set to be rolled out soon.
Reagent 98
98 
Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine
Delveinsight
AUGUST 26, 2021
Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. The study is set to conclude in the fall.
Vaccination 98
98 
Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication
Pharmaceutical Technology
JUNE 8, 2023
The company’s samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses.
Vaccination 130
130 
Pfizer-BioNTech reports strong immune response in animals to its COVID-19 vaccine
The Pharma Data
SEPTEMBER 10, 2020
According to the data, the vaccine candidate conferred “protective anti-viral effects” in rhesus macaque monkeys, as well as concomitant high neutralising antibody titers and a TH1-biased cellular response in both the monkeys and in mice.
AstraZeneca goes bigger in amyloidosis with Neurimmune deal
pharmaphorum
JANUARY 7, 2022
NI006 is an antibody that binds to the misfolded forms of the transthyretin protein that form the fibrils, and cause them to be cleared away by immune cells like macrophages. billion on the first nine months of 2021, well ahead of Pfizer’s own forecasts. Tafamidis is thought to work by stabilising the misfolded proteins.
Antibody 116
116 
ADC Conjugation – An Innovative Approach for Optimizing Targeted Delivery
Roots Analysis
DECEMBER 12, 2023
As a result, innovators came up with the idea of magic bullets, antibody drug conjugates (ADCs). It is comprised of three components, namely antibody, drug and linker. The antibody is conjugated to the drug via a linker molecule. The antibody is conjugated to the drug via a linker molecule. Components of an ADC?
Antibody 40
40 
Gritstone Oncology Devising COVID-19 Vaccine Targeting Future Strains | 2021-01-21
The Pharma Data
JANUARY 20, 2021
based Gritstone Oncology is developing a novel COVID-19 vaccine based on adenovirus and messenger-RNA technology designed to combat future variants of the coronavirus. Emeryville, Calif.-based Louis University. . Source link.
Vaccination 52
52 
This week in drug discovery (22-26 May)
Drug Discovery World
MAY 26, 2023
The top stories: Biopharma investment drops by nearly 50% in 2022 Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. investment to target cancer and neurological diseases PharmEnable has closed a pre-series A investment round of $7.5
Drugs 52
52 
IN FOCUS: Solvias
Pharmaceutical Technology
DECEMBER 9, 2022
Beyond our expertise in small molecules, we have built a solid reputation with biopharmaceutical companies for the characterisation and analysis of monoclonal antibodies, therapeutic proteins and biosimilars. Ribonucleic acid (RNA) based technologies are among many innovative approaches explored to tackle the Covid-19 pandemic.
Development 130
130 
BioNTech, CureVac claim bulk of Germany’s €750m COVID-19 vaccines fund
pharmaphorum
SEPTEMBER 16, 2020
Both of these vaccines are based on RNA and in phase 3 and phase 1 testing, respectively. Earlier clinical data has shown that the vaccine can stimulate neutralising antibodies against SARS-CoV-2 and was well-tolerated with a transient mild to moderate fever being the main side effect seen in less than 20% of recipients.
Vaccination 86
86 
Eli Lilly Announces Nearly $1.5 Billion Investment into New Manufacturing Facilities in North Carolina and Ireland
XTalks
FEBRUARY 3, 2022
The anti-amyloid antibody will go head-to-head against Biogen’s Aduhelm (aducanumab), which continues to face controversy over its approval given questions about its lacklustre clinical benefit. Related: Eli Lilly Pursues RNA Editing in New Partnership with ProQR. Last year, Lilly announced a new, $1.5
Novartis tries to rescue stalled inclisiran filing with FDA
pharmaphorum
JULY 6, 2021
The small interfering RNA (siRNA) therapy has already been approved in Europe as Leqvio , and the FDA’s rejection was not caused by any issues with its efficacy or safety, according to Novartis.
RNA 105
105 
Let's personalize your content